NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

Full Year Total Revenue of $283.5 million Full Year Core Revenue grows 7% year-over-year to $281.2 million Ended 2024 with $828.6 million of cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.87 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Results: Total Revenue of $76.2 million Core Revenue1 grew 14% year-over-year to $76.0 million GAAP loss of $5.9

Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 28, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About F

Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced plans to launch two new germline tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States to identify genetic variants associated with hereditary cancers and can be used by healthcare providers to understand underlying risks for patients and their families. These tests will be offered through a partnership with Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent"). The companies are planning for healthcare providers to be able to add FoundationOne Germline or FoundationOne Germline More to any Foundation Medicine comprehensive genomic profiling test, through Foundation

Total Revenue of $71.7 million Core Revenue grows 9% year-over-year to $71.7 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2024. Third Quarter 2024 Results: Total Revenue of $71.7 million Core Revenue1 grew 9% year-over-year to $71.7 million GAAP loss of $14.6 million, or ($0.48) per share Non-GAAP income of $9.4 million, or $0.31 per share A

Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences: UBS Global Healthcare Conference on Tuesday, November 12th at 2:45 PM Pacific Time Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4th at 11:30 AM Eastern Time Live webcasts of the sessions will be available on the Investor Relations section of the Fulgent website at ir.fulgentgenetics.com. Replay of the webcasts will be accessible at the same location be

Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has been awarded a five-year contract by the U.S. Department of Veterans Affairs (VA) to provide hereditary cancer, pharmacogenetic and other genetic testing to Veterans. A leader in clinical molecular diagnostic testing, Fulgent has been periodically providing genetic testing services to the members of the VA since 2017. These have included both clinical and research-based services. This new award enables Fulgent to provide hereditary cancer tests to individuals with cancer or a family

Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is

Total Revenue of $71.0 million Core Revenue grows 5% year-over-year to $70.2 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2024. Second Quarter 2024 Results: Total Revenue of $71.0 million Core Revenue1 grew 5% year-over-year to $70.2 million GAAP loss of $8.7 million, or ($0.29) per share Non-GAAP income of $4.7 million, or $0.15 per share

Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2024 financial results before the market opens on Friday, August 2, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent

UBS initiated coverage of Fulgent Genetics with a rating of Neutral and set a new price target of $35.00

Piper Sandler downgraded Fulgent Genetics from Overweight to Neutral and set a new price target of $40.00 from $65.00 previously

Raymond James initiated coverage of Fulgent Genetics with a rating of Outperform and set a new price target of $45.00

Credit Suisse initiated coverage of Fulgent Genetics with a rating of Outperform and set a new price target of $65.00

Piper Sandler resumed coverage of Fulgent Genetics with a rating of Overweight and set a new price target of $80.00

Oppenheimer reiterated coverage of Fulgent Genetics with a rating of Outperform and set a new price target of $125.00 from $141.00 previously

Credit Suisse reiterated coverage of Fulgent Genetics with a rating of Underperform and set a new price target of $65.00 from $55.00 previously

Credit Suisse resumed coverage of Fulgent Genetics with a rating of Underperform and set a new price target of $55.00

Piper Sandler reiterated coverage of Fulgent Genetics with a rating of Overweight and set a new price target of $140.00 from $135.00 previously

Piper Sandler reiterated coverage of Fulgent Genetics with a rating of Overweight and set a new price target of $140.00 from $135.00 previously

4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

4/A - Fulgent Genetics, Inc. (0001674930) (Issuer)

4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

DEFA14A - Fulgent Genetics, Inc. (0001674930) (Filer)

DEF 14A - Fulgent Genetics, Inc. (0001674930) (Filer)

SCHEDULE 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

10-K - Fulgent Genetics, Inc. (0001674930) (Filer)

8-K - Fulgent Genetics, Inc. (0001674930) (Filer)

SCHEDULE 13G - Fulgent Genetics, Inc. (0001674930) (Subject)

SCHEDULE 13G - Fulgent Genetics, Inc. (0001674930) (Subject)

144 - Fulgent Genetics, Inc. (0001674930) (Subject)

10-Q - Fulgent Genetics, Inc. (0001674930) (Filer)

8-K - Fulgent Genetics, Inc. (0001674930) (Filer)

NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year

After promising results from first-in-man studies with its novel Neural Ice™ technology, the Massachusetts-based company will use the capital to initiate pivotal clinical studies in both chronic and acute pain indications CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Brixton Biosciences, a spin-out from Massachusetts General Brigham and a clinical stage life sciences company developing novel therapies for chronic and acute pain, today announced that it closed a Series B funding round of $33M. The round was led by Schooner Capital with notable participation by SV Health Investors, Sparta Group, Excelestar Ventures,  PV Capital Management, and Catalyst Health Ventures.

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023. Mr. Kim currently serves as Chief Financial Officer of Fulgent Genetics (NASDAQ:FLGT), a full-service genomic testing company built around a foundational technology platform. He has held that position since February 2016 and led growth initiatives increasing revenues from $10M in 2015 to $990M in 2021, during the COVID-19 era. Mr. Kim has over 30 years working in accounting and finance, and over 15 years as a Chief Financial Officer of several public

Experienced medical and scientific leader will expand Fulgent's reach in molecular diagnostics Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent Genetics" or the "Company"), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced the appointment of Lawrence Weiss, M.D. as Chief Medical Officer, reporting to the Company's Chief Executive Officer, Ming Hsieh. Dr. Weiss will be responsible for expanding Fulgent's reach in molecular diagnostics and driving the advancement of the Company's portfolio of oncologic testing solutions. "We are pleased to welcome Dr. Weiss to our team to oversee the expansion of our strategy around molecu

Full Year Total Revenue of $283.5 million Full Year Core Revenue grows 7% year-over-year to $281.2 million Ended 2024 with $828.6 million of cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.87 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Results: Total Revenue of $76.2 million Core Revenue1 grew 14% year-over-year to $76.0 million GAAP loss of $5.9

Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 28, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About F

Total Revenue of $71.7 million Core Revenue grows 9% year-over-year to $71.7 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2024. Third Quarter 2024 Results: Total Revenue of $71.7 million Core Revenue1 grew 9% year-over-year to $71.7 million GAAP loss of $14.6 million, or ($0.48) per share Non-GAAP income of $9.4 million, or $0.31 per share A

Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is

Total Revenue of $71.0 million Core Revenue grows 5% year-over-year to $70.2 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2024. Second Quarter 2024 Results: Total Revenue of $71.0 million Core Revenue1 grew 5% year-over-year to $70.2 million GAAP loss of $8.7 million, or ($0.29) per share Non-GAAP income of $4.7 million, or $0.15 per share

Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2024 financial results before the market opens on Friday, August 2, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent

Total Revenue of $64.5 million Core Revenue grows 1% year-over-year to $63.2 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2024. First Quarter 2024 Results: Total Revenue of $64.5 million Core Revenue1 grew 1% year-over-year to $63.2 million GAAP loss of $13.5 million, or $0.45 per share Non-GAAP loss of $269,000, or $0.01 per share Adjusted EBITDA loss of $3.2 million Cash from o

Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2024 financial results before the market opens on Friday, May 3, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is a

Full Year 2023 Total Revenue of $289.2 million; Q4 2023 Total Revenue of $70.5 million Full Year 2023 Core Revenue grows 44% year-over-year to $262.1 million; Q4 2023 Core Revenue grows 21% year-over-year to $66.5 million Ended 2023 with $847.7 million of cash, cash equivalents, and investments in marketable securities, representing cash per share of $28 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Results: Total Revenue

Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 28, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. Abou

SC 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)

SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

SC 13G - Fulgent Genetics, Inc. (0001674930) (Subject)

SC 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)

SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

SC 13G - Fulgent Genetics, Inc. (0001674930) (Subject)